Slide 1: LIFT Study Topline Results: A 12-Week Phase 2a Trial of TERN-101 in NASH Patients
TERNS PHARMACEUTICALS LIFT Study Topline Results A 12-Week Phase 2a Trial of TERN-101 in NASH Patients June 14th, 2021 NASDAQ: TERN
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements about Terns Pharmaceuticals, Inc. (the “Company,” “we,” “us,” or “our”) and its industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this prese
Slide 3: Terns Pipeline: Designed to Address Multifaceted Nature of NASH
TfUFT Terns would like to acknowledge and thank theerns Pipeline: Designed to Address Multifaceted Nature of NASH Combining candidateswith complementary mechanisms to maximize NASH response rates patients, investigators, and LIT study team,
Slide 4: LIFT: Important Firsts for NASH Treatment
3LIFT 3 Important Firsts for NASH Treatment First FXR agonist trial to demonstrate no discontinuations due to AEs, including pruritus - TERN-101 was generally well-tolerated with similar incidence of AEs across treatment groups - No treatment-related SAEs First 12-week controlled trial in NASH to sh
Slide 5: Terns Pipeline: Designed to Address Multifaceted Nature of NASH
Terns Pipeline: Designed to Address Multifaceted Nature of NASH Combining candidates with complementary mechanisms to maximize NASH respo nse rates
Slide 6: TERN-101: A Differentiated Liver-Distributed FXR Agonist
TERN-101: A Differentiated Liver-Distributed FXR Agonist
Slide 7: LIFT Phase 2a Trial in Patients with NASH
^LIFT Phase 2a Trial in Patients with NASH Primary objective: Safety assessment Secondary /exploratory objectives: ALT, PK, cT1, MRI-PDFF, and other biomarkers Randomized, Double Blind NAH patients based on clinical characteristics or prior biopsy with fibrosis but not cirrhosis
Slide 8: Exploratory Endpoints Include Multi-parametric MR Imaging: MRI-PDFF & cT1
Exploratory Endpoints Include Multi-parametric MR Imaging: MRI-PDFF & Corrected T1 (cT1)
Slide 9: cT1 is Correlated with Liver Histology
cT1 is Correlated with Liver Histology Both PDFF and cT1 correlated with NAS, but only cT1 correlates with fibrosis cT1 was also correlated with fibrosis and was superior to PDFF for detection of fibrosis and inflammation Source: Dennis, et al 2021 Front. Endocrinol. 1. Mean cT1 baseline range of LI
Slide 10: Patient Disposition: High Rate of Completion
Patient Disposition: High Rate of Completion No patient discontinued TERN-101 or placebo due to adverse events including pruritus
Slide 11: Baseline Characteristics: Balanced Across Treatment Arms
Baseline Characteristics: Balanced Across Treatment Arms Representative of High-risk F2/F3 NASH Population
Slide 12: Primary Objective Safety Summary: Well Tolerated
Primary Objective Safety Summary: Well Tolerated with No Discontinuations Due to Any AE No treatment-related serious adverse events were observed
Slide 13: Most Frequent Treatment-Emergent Adverse Events
Most Frequent Treatment-Emergent Adverse Events All treatment-related AEs were mild/moderate with no apparent dose-relationship Pruritus: no Grade 3; no discontinuations; most resolved with continued dosing
Slide 14: Minimal Lipid Changes in TERN-101 5mg and 10mg Cohorts
Minimal Lipid Changes in TERN-101 5mg and 10mg Cohorts
Slide 15: ALT, AST, GGT, ALP: Mean % Change from Baseline
ALT: Mean % Change (SE) from Baseline AST: Mean % Change (SE) from Baseline GGT: Mean % Change (SE) from Baseline SE = Standard error 15 ALP: Mean % Change (SE) from Baseline
Slide 16: Improvement in Liver Fat Content (MRI-PDFF)
Improvement in Liver Fat Content (MRI-PDFF) MRI-PDFF Mean Relative Change (SE) from Baseline [%] Week 12
Slide 17: LIFT is the First Trial in NASH Patients to Show Significant Improvements in cT1
^LIFT is the First Trial in NASH Patients to Show Significant Improvements in cT1 Starting as Early as 6 Weeks cT1 Mean Change (SE) from Baseline [msec] TERNS PHARMACEUTICALS
Slide 18: Substantially More Patients in Each TERN-101 Cohort Had Improvements in cT1
Substantially More Patients in Each TERN-101 Cohort Had Improvements in cT1 % with > 80 msec 18 decline at Week 12
Slide 19: LIFT Patient Case Studies: Changes in cT1
^LIFT Patient Case Studies: Changes in cT1
Slide 20: cT1 is Significantly Correlated with Clinical Outcomes
cT1 is Significantly Correlated with Clinical Outcomes cT1 and Histology Have Shown Equivalent Performance for Predicting Clinical Outcomes cT1, but not MRI-PDFF, correlated with clinical outcomes
Slide 21: cT1 Results in Context of Late-Stage NASH Investigational Products
cT1 Results in Context of Late-Stage NASH Investigational Products TERN-101 cT1 changes comparable to late-stage development candidates
Slide 22: cT1 Results in Context of Late-Stage NASH Investigational Products
cT1 Results in Context of Late-Stage NASH Investigational Products TERN-101 cT1 changes comparable to late-stage development candidates
Slide 23: LIFT: Important Firsts for NASH Treatment
3LIFT 3 Important Firsts for NASH Treatment First FXR agonist trial to demonstrate no discontinuations due to AEs, including pruritus TERN-101 was generally well-tolerated with similar incidence of AEs across treatment groups No treatment-related SAEs First 12-week controlled trial in NASH to show s
Slide 24: Terns Pipeline: Multiple Catalysts Over the Next Months
Terns Pipeline: Multiple Catalysts Over the Next 12 Months Combining candidates with complementary mechanisms to maximize NASH patient benefit
Slide 25: Appendix
Appendix
Slide 26: Key Completed and Upcoming Milestones
Key Completed and Upcoming Milestones Multiple clinical milestones in 2021/2022 in preparation for combo trials
Slide 27: TERN-501: Differentiated THR-beta Agonist
TERN-501: Differentiated THR-0 AgonistTHR-p regulates key aspects of energy metabolism (e.g., fatty acid & lipid synthesis, liver fat removal through fatty acid oxidation) • TERN-501 is a selective Thyroid Hormone Receptor beta (THR-p) agonist with enhanced metabolic stability and liver distribution
Slide 28: TERN-501: Improved PK & THR-beta Selectivity
TERN-501: Improved PK & THR-0 Selectivity Differentiated and excellent candidate for co-formulation TERN-501: Improved Pharmacokinetics
Slide 29: TERN-501: Single Dose Suppresses Cholesterol
TERN-501: Single Dose Suppresses Cholesterol Improved potency relative to resmetirom
Slide 30: TERN-501 Activity in DIO/CCl4 NASH Model
I TERN-501 Activity in DIO/CCI4 NASH Model I Liver histology, liver function, lipid parameter improvements
Slide 31: TERN-101+TERN-501 Combination NASH Model
TERN-101+TERN-501 Combination NASH Model Combination shows additional effects on steatosis and fibrosis improvement